688185.SH
康希诺
SSE · Healthcare · Biotechnology · CN
CNY 75.50
−2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 846.3M | 357.1M | 1.0B |
| Cost of Revenue | 252.7M | 240.2M | 204.5M | 259.4M | 416.4M |
| Gross Profit | 868.4M | 827.7M | 641.8M | 97.7M | 618.2M |
| Operating Expenses | |||||
| R&D Expense | 311.7M | 313.0M | 416.1M | 638.0M | 778.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 159.2M | 158.4M | 178.7M | 286.5M | 268.9M |
| Selling & Marketing Expense | 439.1M | 416.7M | 369.1M | 353.4M | 266.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 953.7M | 925.4M | 951.9M | 1.2B | 1.1B |
| Cost and Expenses | 1.2B | 1.2B | 1.2B | 1.5B | 1.6B |
| Operating Income (EBIT) | 6.1M | 23.9M | (375.2M) | (1.9B) | (1.2B) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 4.0M | 21.7M | (381.2M) | (2.0B) | (1.2B) |
| Income Tax Expense | 5.0M | (6.1M) | 2.5M | (11.5M) | (219.2M) |
| Bottom Line | |||||
| Net Income | (1.0M) | 27.9M | (378.9M) | (1.5B) | (909.4M) |
| Earnings from Cont. Ops | (1.0M) | 27.9M | (383.7M) | (2.0B) | (964.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.0M) | 27.9M | (378.9M) | (1.5B) | (909.4M) |
| Per Share | |||||
| Basic EPS | CN¥0.00 | CN¥0.11 | (CN¥1.53) | (CN¥6.01) | (CN¥3.68) |
| Diluted EPS | CN¥0.00 | CN¥0.11 | (CN¥1.53) | (CN¥6.01) | (CN¥3.68) |
| Revenue Per Share | CN¥4.44 | CN¥4.21 | CN¥3.42 | CN¥1.45 | CN¥4.19 |
| Shares | |||||
| Basic Shares Outstanding | 252.7M | 253.4M | 247.6M | 246.7M | 247.1M |
| Diluted Shares Outstanding | 252.7M | 253.4M | 247.6M | 246.7M | 247.1M |
| Profitability Metrics | |||||
| EBITDA | — | 195.0M | (173.7M) | (1.7B) | (993.4M) |
| D&A | — | 171.1M | 201.6M | 246.2M | 187.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026